Risk Factors for Readmission Following Febrile Neutropenia in Pediatric Oncology Patients
- PMID: 36346651
- DOI: 10.1097/MPH.0000000000002585
Risk Factors for Readmission Following Febrile Neutropenia in Pediatric Oncology Patients
Abstract
Febrile neutropenia is the most common reason for admission from the emergency department for pediatric oncology patients. We identified pediatric inpatients age 1 to 21 years with an International Classification of Diseases, Ninth Revision (ICD-9) diagnosis code of malignancy and either fever with neutropenia or fever alone over a 6-year period (2007-2012) using the PHIS+ database. We evaluated factors associated with readmission within 7 days after index hospitalization. There were 4029 index hospitalizations among 2349 patients in 6 hospitals, 294 encounters (7.3%) were followed by readmission within 7 days. Factors associated with increased odds of readmission included being in the lowest quartile for median household income (odds ratio [OR]=1.64, P =0.009), diagnosis of acute lymphoblastic leukemia (OR=1.37, P =0.016), lack of anerobic coverage during index hospitalization (OR=1.48, P =0.026), and absolute neutrophil count <200 cells/μL at discharge from index hospitalizations (OR=1.55, P =0.008). Patients who required readmission had a longer median length of stay and greater hospitalization costs during the index hospitalization. There was a trend towards increasing hospitalization rates for febrile neutropenia over time. While absolute neutrophil count is incorporated into many risk stratification strategies for fever management, further work should focus on addressing socioeconomic factors which may impact readmission rates.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- Mueller EL, Sabbatini A, Gebremariam A, et al. Why pediatric patients with cancer visit the emergency department: United States, 2006-2010. Pediatr Blood Cancer. 2015;62:490–495.
-
- Zimmer AJ, Freifeld AG. Optimal management of neutropenic fever in patients with cancer. J Oncol Pract. 2019;15:19–24.
-
- Alali M, Mayampurath A, Dai Y, et al. A prediction model for bacteremia and transfer to intensive care in pediatric and adolescent cancer patients with febrile neutropenia. Sci Rep. 2022;12:7429.
-
- Alali M, David MZ, Danziger-Isakov LA, et al. Pediatric febrile neutropenia: change in etiology of bacteremia, empiric choice of therapy and clinical outcomes. J Pediatr Hematol Oncol. 2020;42:e445–e451.
-
- Agyeman P, Kontny U, Nadal D, et al. A prospective multicenter study of microbiologically defined infections in pediatric cancer patients with fever and neutropenia: Swiss Pediatric Oncology Group 2003 fever and neutropenia study. Pediatr Infect Dis J. 2014;33:e219–e225.
MeSH terms
LinkOut - more resources
Full Text Sources